RxDoctor Payments Data

Edward Tristine, MD

Internal Medicine · Trumbull, CTNPI 1881700631

Payments from drug & device makers

$4,360in general payments, 2019–2025

Across 244 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$875
  • Novo Nordisk$689
  • Pfizer$494
  • Boehringer Ingelheim$410
  • Lilly USA, LLC$383
  • AstraZeneca$295
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,354100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,360 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$164,162
Medicare patients
471
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban989$188,013
OzempicSemaglutide143$173,144
JardianceEmpagliflozin175$157,113
Xeljanz XrTofacitinib Citrate11$47,755
RexultiBrexpiprazole98$45,355
TrulicityDulaglutide36$35,879
Abilify MaintenaAripiprazole11$34,251
MyrbetriqMirabegron122$32,563
JanumetSitagliptin Phos/Metformin Hcl31$31,180
XareltoRivaroxaban100$31,032
TradjentaLinagliptin141$29,057
FarxigaDapagliflozin Propanediol105$26,315
LinzessLinaclotide37$26,142
JanuviaSitagliptin Phosphate41$23,906
TeflaroCeftaroline Fosamil Acetate36$22,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$494$188,013989 claims
Boehringer IngelheimJardiance, Tradjenta$410$186,170316 claims
Novo NordiskOzempic$689$173,144143 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$39$79,607109 claims
MerckJanumet, Januvia$135$55,08772 claims
Lilly USA, LLCTrulicity, Mounjaro$383$53,91953 claims
AstraZenecaFarxiga, Symbicort, Brilinta$295$49,121226 claims
AbbVieLinzess, Teflaro$875$48,52573 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$264$41,37181 claims
Astellas Pharma US IncMyrbetriq$66$32,563122 claims
Johnson & JohnsonXarelto$89$31,032100 claims
NovartisEntresto$171$6,53039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →